Drawing for ICONIMAC

USPTO serial 88054356

ICONIMAC

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CORWIN, CHARLOTTE K
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ICONIMAC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Aaron D. Hendelman

Aaron D. Hendelman WILSON SONSINI GOODRICH & ROSATI650 PAGE MILL ROADPALO ALTO, CA 94304-1050UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals for the purpose of treating life-threatening diseases; pharmaceuticals for use in the fields of biotechnology and immune therapeutics; pharmaceutical products, namely, innate immunity cell-based therapeutics; pharmaceuticals for the treatment of infectious disease, autoimmunity, neurodegeneration, and aging; pharmaceuticals for addressing underlying innate immune dysfunction, including in connection with infectious diseases, autoimmune diseases, neurologic diseases, cancer, Parkinson's, Alzheimer's, and dementia; pharmaceuticals for addressing a wide variety of diseases, including pulmonary diseases, fibrosis, and protein aggregation diseases; pharmaceutical preparations, namely, cell-based therapeutics to augment innate immune responses; pharmaceutical preparations, namely, a drug delivery system for the continuous release of a wide variety of therapeutic agents; vaccines; vaccine preparationsACTIVE—
042Biotechnology research; immune therapeutics research; research and development in the biotechnology and immune therapeutics fields; development of new technology in the field of biotechnology to augment innate immune responses; development of new biotechnology, namely, using augmented innate immune responses to promote the treatment of infectious disease, autoimmunity, neurodegeneration, and aging; development of new biotechnology, namely, pharmaceuticals for addressing underlying innate immune dysfunction, including in connection with infectious diseases, autoimmune diseases, neurologic diseases, cancer, Parkinson's, Alzheimer's, and dementia; development of new biotechnology, namely, pharmaceuticals for addressing a wide variety of diseases, including pulmonary diseases, fibrosis, and protein aggregation diseases; conducting clinical trials in the field of biotechnology; clinical research in the field of immune therapeutics; clinical research in the field of vaccines; research and development of vaccines and medicines; conducting research and clinical trials relating to innate immunity cell-based therapeutics; medical research services in the fields of biotechnology and immune therapeuticsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 21, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 21, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 2, 2020DOCKASSIGNED TO EXAMINER—
Feb 18, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 14, 2020EX2GSOU EXTENSION 2 GRANTED—
Feb 14, 2020EXT2SOU EXTENSION 2 FILED—
Feb 14, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 12, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 10, 2019EX1GSOU EXTENSION 1 GRANTED—
Jun 10, 2019EXT1SOU EXTENSION 1 FILED—
Jun 10, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 19, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 25, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 25, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 5, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 14, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 13, 2018DOCKASSIGNED TO EXAMINER—
Aug 1, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 30, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance